Study: Many approved cancer drugs lack proof of added benefit

Many cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedited (“fast track”) pathways, finds a study published by The BMJ today.

IGEA to update on SIX decision – Biotech Investments

IGEA Pharma N.V. / Key word(s): Delisting/Delisting 04-Aug-2023 / 22:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is

August 5, 2023

Risk Adjusted Net Present Value: What is the current valuation of Legend Biotech’s LB-1908

The revenue for LB-1908 is expected to reach an annual total of $27 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue

September 19, 2023

Understanding how stress accelerates cancer spread

Stress is inevitable. But too much of it can be terrible for our health. Chronic stress can increase our risk for heart disease and strokes.

February 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.